Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Average Price Target from Brokerages
by Jessica Moore · The Cerbat GemShares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) have been given an average rating of “Hold” by the three brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $17.00.
A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th.
Check Out Our Latest Stock Report on VRCA
Verrica Pharmaceuticals Stock Performance
Shares of VRCA stock opened at $6.27 on Tuesday. The stock has a market capitalization of $107.72 million, a P/E ratio of -6.09 and a beta of 1.54. The company has a current ratio of 2.10, a quick ratio of 2.45 and a debt-to-equity ratio of 0.03. The firm’s 50 day moving average is $6.07 and its 200 day moving average is $6.33. Verrica Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $9.82.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. The company had revenue of $5.02 million for the quarter, compared to analysts’ expectations of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. On average, sell-side analysts anticipate that Verrica Pharmaceuticals will post -1.84 earnings per share for the current year.
Hedge Funds Weigh In On Verrica Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp grew its holdings in shares of Verrica Pharmaceuticals by 14.1% during the 4th quarter. State Street Corp now owns 23,481 shares of the company’s stock valued at $195,000 after purchasing an additional 2,900 shares during the last quarter. Renaissance Technologies LLC boosted its position in Verrica Pharmaceuticals by 22.6% during the 1st quarter. Renaissance Technologies LLC now owns 32,360 shares of the company’s stock valued at $171,000 after buying an additional 5,960 shares during the period. Man Group plc purchased a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $94,000. Quadrature Capital Ltd purchased a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $99,000. Finally, Beck Mack & Oliver LLC purchased a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $100,000. Institutional investors own 42.45% of the company’s stock.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.
Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.